Article info

Download PDFPDF

Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al

Authors

  1. Correspondence to Dr Elizabeth D Mellins, Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA 94305, USA; mellins{at}stanford.edu
View Full Text

Citation

Saper VE, Chen G, Khatri P, et al
Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al

Publication history

  • Received February 2, 2020
  • Accepted February 3, 2020
  • First published February 13, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.